Dr. Khan is vice president of chemistry research and development at Aptinyx. Prior to Aptinyx, he was vice president of chemistry research and development at Naurex. Dr. Khan has over 20 years of experience as a senior chemist at several biotechnology companies, including Elan and Gliatech. Dr. Khan has discovered and developed multiple novel central nervous system molecules that have entered human clinical trials, including many NMDA receptor modulators. Dr. Khan received a B.S. and B.Ed. from the Regional Institute of Education, Bhopal, India, and an M.S. and Ph.D. from Kanpur University in India. He was a postdoctoral fellow at the Indian Institute of Technology, Kanpur, India.
Upgrade to view 1 report
This person is not in any offices
Aptinyx
Aptinyx is a biopharmaceutical company discovering and developing innovative therapies for challenging disorders of the brain and nervous system, starting with painful diabetic neuropathy, fibromyalgia, PTSD, and Parkinson’s cognitive impairment.